GlaxoSmithKline Czech Republic - Indebtedness

Net Debt/EBITDA & Net Debt/Equity
Pharmaceutical | Czech Republic | March 19, 2018
$2.99
Excel Sheet

GlaxoSmithKline Czech Republic's net debt reached CZK -515 mil and accounted for -0.385 of equity at the end of 2015. The ratio is down 259559% when compared to the previous year.

Historically, the firm’s net debt to equity reached an all time high of 0.400 in 2008 and an all time low of -0.385 in 2015.

When compared to EBITDA, net debt amounted to -3.71x at the end of the year. The ratio reached an all time high of 2.74 in 2008 and an all time low of -3.86 in 2003.

As far as GlaxoSmithKline Czech Republic's peers are concerned, Roche Czech Republic posted net debt to equity of 0.557x and 3.15x when compared to EBITDA at the end of 2015. Bayer Czech Republic ended the year 2015 with a net debt at 0.608x of equity and 0.890x when compared to its EBITDA while Bayer Czech Republic had net debt at 0.608x of equity and 0.890x to EBITDA at the end of the year.

You can see all the company’s data at GlaxoSmithKline Czech Republic Profile, or you can download a report on the company in the report section.